Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ECs in Canada

This article was originally published in The Tan Sheet

Executive Summary

Women's Capital Corp.'s progestin-only morning-after pill, Plan B, could be available "behind-the-counter" in Canada within a year, group says. WCC submitted an application to Health Canada March 6 to switch the EC from prescription-only to nonprescription status; if approved, Plan B would be dispensed by trained pharmacists operating under a protocol developed by the Canadian Pharmacists Association and Society of Obstetricians & Gynecologists of Canada. Application includes results from a label comprehension study of 600 American women, as well as post-marketing safety data from Europe. WCC also is in final stages of an actual-use study involving 600 women in Washington; once it is complete, the group will have enough information to submit an application to FDA, which it plans for late summer...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel